MPT: Evolocumab's Absolute Benefit Greater in PAD Patients

ACC Conference Reporter

AHA 2017 | ANAHEIM — Atherosclerosis is not a focal disease, thus it was expected that the PCSK-9 inhibitor evolocumab (Repatha), which already demonstrated impressive LDL-lowering as well as a reduction in cardiovascular events, could also reduce the risk of acute peripheral vascular events -- and that is exactly what was reported here. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA17


< Back to Listings